Joanne Wuensch
Stock Analyst at Citigroup
(4.42)
# 315
Out of 4,918 analysts
398
Total ratings
65.17%
Success rate
11.89%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies | Maintains: Buy | $89 → $93 | $70.64 | +31.65% | 6 | Jul 31, 2025 | |
| PEN Penumbra | Maintains: Neutral | $320 → $285 | $240.39 | +18.56% | 25 | Jul 9, 2025 | |
| MDT Medtronic | Maintains: Buy | $98 → $99 | $89.64 | +10.44% | 20 | Jul 9, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Neutral | $38 → $47 | $42.75 | +9.94% | 7 | Jul 9, 2025 | |
| BAX Baxter International | Maintains: Neutral | $34 → $32 | $22.44 | +42.60% | 21 | Jul 9, 2025 | |
| BLCO Bausch + Lomb | Maintains: Neutral | $13 → $15 | $13.72 | +9.33% | 6 | Jul 9, 2025 | |
| HAE Haemonetics | Upgrades: Buy | $71 → $90 | $76.30 | +17.96% | 8 | Jul 9, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Sell | $24 → $14 | $15.42 | -9.21% | 17 | Jul 9, 2025 | |
| SYK Stryker | Maintains: Buy | $443 → $455 | $381.49 | +19.27% | 14 | May 22, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $3.2 → $3.6 | $3.46 | +4.05% | 11 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $4.15 | $1.65 | +151.52% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $167 | $164.98 | +1.22% | 19 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $590 → $650 | $483.36 | +34.48% | 17 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $380 | $287.77 | +32.05% | 16 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $80.09 | +18.62% | 20 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $102 | $76.25 | +33.77% | 14 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $119 → $125 | $106.79 | +17.05% | 35 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $133 → $140 | $106.83 | +31.05% | 6 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $110 | $71.45 | +53.95% | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $160 | $129.93 | +23.14% | 20 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $185 → $175 | $171.04 | +2.32% | 12 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $132 → $162 | $87.50 | +85.14% | 20 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $22 | $12.57 | +75.02% | 14 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $134 → $120 | $92.40 | +29.87% | 22 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $178.90 | +39.74% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $87.82 | -21.43% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $291.44 | -56.42% | 6 | Dec 10, 2018 |
GE HealthCare Technologies
Jul 31, 2025
Maintains: Buy
Price Target: $89 → $93
Current: $70.64
Upside: +31.65%
Penumbra
Jul 9, 2025
Maintains: Neutral
Price Target: $320 → $285
Current: $240.39
Upside: +18.56%
Medtronic
Jul 9, 2025
Maintains: Buy
Price Target: $98 → $99
Current: $89.64
Upside: +10.44%
Establishment Labs Holdings
Jul 9, 2025
Maintains: Neutral
Price Target: $38 → $47
Current: $42.75
Upside: +9.94%
Baxter International
Jul 9, 2025
Maintains: Neutral
Price Target: $34 → $32
Current: $22.44
Upside: +42.60%
Bausch + Lomb
Jul 9, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $13.72
Upside: +9.33%
Haemonetics
Jul 9, 2025
Upgrades: Buy
Price Target: $71 → $90
Current: $76.30
Upside: +17.96%
Tandem Diabetes Care
Jul 9, 2025
Downgrades: Sell
Price Target: $24 → $14
Current: $15.42
Upside: -9.21%
Stryker
May 22, 2025
Maintains: Buy
Price Target: $443 → $455
Current: $381.49
Upside: +19.27%
Sight Sciences
May 22, 2025
Maintains: Neutral
Price Target: $3.2 → $3.6
Current: $3.46
Upside: +4.05%
May 22, 2025
Maintains: Neutral
Price Target: $6.5 → $4.15
Current: $1.65
Upside: +151.52%
May 22, 2025
Maintains: Buy
Price Target: $130 → $167
Current: $164.98
Upside: +1.22%
May 22, 2025
Maintains: Buy
Price Target: $590 → $650
Current: $483.36
Upside: +34.48%
May 22, 2025
Maintains: Buy
Price Target: $320 → $380
Current: $287.77
Upside: +32.05%
May 22, 2025
Maintains: Buy
Price Target: $84 → $95
Current: $80.09
Upside: +18.62%
May 22, 2025
Maintains: Buy
Price Target: $82 → $102
Current: $76.25
Upside: +33.77%
May 22, 2025
Maintains: Buy
Price Target: $119 → $125
Current: $106.79
Upside: +17.05%
May 22, 2025
Upgrades: Buy
Price Target: $133 → $140
Current: $106.83
Upside: +31.05%
Mar 7, 2025
Maintains: Buy
Price Target: $115 → $110
Current: $71.45
Upside: +53.95%
Mar 4, 2025
Maintains: Buy
Price Target: $135 → $160
Current: $129.93
Upside: +23.14%
Dec 11, 2024
Maintains: Buy
Price Target: $185 → $175
Current: $171.04
Upside: +2.32%
Dec 11, 2024
Upgrades: Buy
Price Target: $132 → $162
Current: $87.50
Upside: +85.14%
Nov 5, 2024
Maintains: Sell
Price Target: $16 → $22
Current: $12.57
Upside: +75.02%
Jul 10, 2024
Maintains: Neutral
Price Target: $134 → $120
Current: $92.40
Upside: +29.87%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $178.90
Upside: +39.74%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $87.82
Upside: -21.43%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $291.44
Upside: -56.42%